404 related articles for article (PubMed ID: 31663464)
1. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
2. Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.
Jung J; Feldman R
J Racial Ethn Health Disparities; 2017 Dec; 4(6):1147-1158. PubMed ID: 27928769
[TBL] [Abstract][Full Text] [Related]
3. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of new hepatitis C drugs among Medicare patients.
Jung J; Du P; Feldman R; Riley T
Am J Manag Care; 2020 Feb; 26(2):84-88. PubMed ID: 32059096
[TBL] [Abstract][Full Text] [Related]
5. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
6. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.
Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Socioeconomic and Geographical Characteristics of Beneficiaries Receiving a Comprehensive Medication Review.
Chou J; Pellegrin K; Cooke CE; Zarowitz B; Hanlon A; Lozano A; Brandt NJ
J Manag Care Spec Pharm; 2020 Oct; 26(10):1276-1281. PubMed ID: 32996388
[TBL] [Abstract][Full Text] [Related]
8. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
9. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
[TBL] [Abstract][Full Text] [Related]
10. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.
Kanwal F; Kramer JR; El-Serag HB; Frayne S; Clark J; Cao Y; Taylor T; Smith D; White D; Asch SM
Clin Infect Dis; 2016 Aug; 63(3):291-9. PubMed ID: 27131869
[TBL] [Abstract][Full Text] [Related]
11. Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson D; Guo J; Lo-Ciganic WH; Park H
Med Care; 2023 Feb; 61(2):81-86. PubMed ID: 36453625
[TBL] [Abstract][Full Text] [Related]
12. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
13. Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C.
Tran L; Jung J; Carlin C; Lee S; Zhao C; Feldman R
J Alzheimers Dis; 2021; 79(1):71-83. PubMed ID: 33216031
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.
Kaplan DE; Serper M; Kaushik A; Durkin C; Raad A; El-Moustaid F; Smith N; Yehoshua A
J Manag Care Spec Pharm; 2022 Oct; 28(10):1138-1148. PubMed ID: 36125059
[No Abstract] [Full Text] [Related]
15. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
16. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
Sims OT; Guo Y; Shoreibah MG; Venkata K; Fitzmorris P; Kommineni V; Romano J; Massoud OI
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1219-1222. PubMed ID: 28857899
[TBL] [Abstract][Full Text] [Related]
17. Eligibility Criteria for Lower Extremity Joint Replacement May Worsen Racial and Socioeconomic Disparities.
Wang AY; Wong MS; Humbyrd CJ
Clin Orthop Relat Res; 2018 Dec; 476(12):2301-2308. PubMed ID: 30303879
[TBL] [Abstract][Full Text] [Related]
18. Racial Disparities in Readmission Rates among Patients Discharged to Skilled Nursing Facilities.
Rivera-Hernandez M; Rahman M; Mor V; Trivedi AN
J Am Geriatr Soc; 2019 Aug; 67(8):1672-1679. PubMed ID: 31066913
[TBL] [Abstract][Full Text] [Related]
19. Did Medicare Part D reduce disparities?
Zissimopoulos J; Joyce GF; Scarpati LM; Goldman DP
Am J Manag Care; 2015 Feb; 21(2):119-28. PubMed ID: 25880361
[TBL] [Abstract][Full Text] [Related]
20. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
